Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Medical College of Wisconsin
Merck Sharp & Dohme LLC
University of Kentucky
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
University of Michigan Rogel Cancer Center
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Milton S. Hershey Medical Center
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
University of California, San Diego
Mayo Clinic
National Cancer Institute (NCI)
Yale University
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Radiation Therapy Oncology Group
Boehringer Ingelheim
University of Pittsburgh
Varian, a Siemens Healthineers Company
Memorial Sloan Kettering Cancer Center
I-Mab Biopharma US Limited
University of Texas Southwestern Medical Center
University of California, San Francisco
Merck Sharp & Dohme LLC
Incyte Corporation
Wake Forest University Health Sciences
Washington University School of Medicine
University of Connecticut
Medical University of South Carolina
University of Florida
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Southern California
University of Arkansas
Sanford Health
Sanofi
Sanofi
Massachusetts General Hospital
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
University of Arkansas
University of Wisconsin, Madison
Academic and Community Cancer Research United
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
MacroGenics